Isomorphic Labs secured the fresh funding following positive preclinical results in its oncology and immunology programs. The company builds on the Nobel Prize-winning AlphaFold platform by using multiple simulation AI models to investigate chemical structures and engineer novel therapies. With major pharmaceutical partnerships already established alongside Eli Lilly, Novartis, and Johnson & Johnson, the capital will expand the reach of its proprietary drug-design engine.
Key points
Heavy backing from global venture firms demonstrates surging confidence in applying gener…: Heavy backing from global venture firms demonstrates surging confidence in applying generative protein-prediction models to clinical pipeline development.
Deep collaboration with major pharmaceutical partners indicates commercial readiness to t…: Deep collaboration with major pharmaceutical partners indicates commercial readiness to transition theoretical computational chemistry into clinical-stage drug testing.
The platform leverages the foundational AlphaFold architecture to move past protein model…: The platform leverages the foundational AlphaFold architecture to move past protein modeling into direct chemical design and treatment simulation.
Sources checked by our analysis pipeline: 1
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.
The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.
Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model, said its program has yielded “positive preclinical results” in oncology and immunology. The lab has struck deals with pharma giants like Eli Lilly, Novartis, and Johnson & Johnson.
The new funding, which comes on the heels of a $2.1 billion Series B round in May, will be used to continue developing its drug-design engine, as well as to foray into…
The artificial intelligence company is attempting to broaden access by reserving shares for retail participants during its public debut. However, the strategy is encountering immediate pushback from observers who are actively declining to participate. Detractors view the effort with deep skepticism, arguing that market sentiment around the firm is heavily exaggerated.
Former executives from Uber and Google Maps are betting that generalized artificial intelligence cannot handle the intricate, prolonged logistics required for modern trip coordination. The startup's newly secured capital will finance technical recruitment and the industry partnerships needed to build a dedicated booking ecosystem. This specialized approach aims to manage travel logistics continuously from early planning stages through the journey's end.
Rapid artificial intelligence expansion is clashing with intense local resistance and mounting political scrutiny over critical resources. To help investors navigate these growing bottlenecks, new predictive modeling measures disruption risks that threaten capital allocation across thousands of regional markets. This analytical approach addresses widening gaps between aggressive infrastructure funding and slow-moving regulatory approval processes.